International Clinical Trial: A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816185) titled 'A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Pulmovant, Inc.

Condition: Pulmonary Hypertension Interstitial Lung Disease Vascular Diseases Cardiovascular Diseases Fibrosis

Intervention: Drug: Mosliciguat Drug: Placebo

Recruitment Status: Recruiting

Phase: Phase 3

Date of First Enrollment: August 31, 2026

Target Sample Size: 376

Countries of Rec...